General Information of the Compound
| Compound ID |
CP0049566
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
15-28-Somatostatin-28
Show/Hide
|
||||||||||||||||||
| Synonyms |
51110-01-1
61950-59-2
AY 24910
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys
Aminopan
CCRIS 7071
EINECS 256-969-7
Growth hormone release inhibiting factor
Growth hormone release-inhibiting factor
Growth hormone release-inhibiting hormone
NCGC00181005-01
Panhibin
SCHEMBL3046327
SOMATOSTATIN
SRIF
Somatostatin 1-14
Somatostatin acetate
Somatotropin release-inhibiting factor
Somatotropin release-inhibiting hormone
Somiaton
[D-Trp8]-SOMATOSTATIN
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C76H104N18O19S2
|
||||||||||||||||||
| Molecular Weight |
1637.909
|
||||||||||||||||||
| Canonical SMILES |
C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42+,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-,63-/m0/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
NHXLMOGPVYXJNR-ATOGVRKGSA-N
|
||||||||||||||||||
| CAS |
38916-34-6
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00930, Somatostatin receptor type 1
Cell-based Assay
Protein ID: PT01505, Somatostatin receptor type 2
Cell-based Assay
Protein ID: PT01693, Somatostatin receptor type 3
Cell-based Assay
Protein ID: PT01398, Somatostatin receptor type 4
Cell-based Assay
Protein ID: PT01196, Somatostatin receptor type 5
Cell-based Assay
Clinical Information about the Compound
Drug 1 ( SOMATOSTATIN )
| Drug Name | SOMATOSTATIN | ||
|---|---|---|---|
| Target(s) | |||